Unknown

Dataset Information

0

Management of Brain and Leptomeningeal Metastases from Breast Cancer.


ABSTRACT: The management of breast cancer (BC) has rapidly evolved in the last 20 years. The improvement of systemic therapy allows a remarkable control of extracranial disease. However, brain (BM) and leptomeningeal metastases (LM) are frequent complications of advanced BC and represent a challenging issue for clinicians. Some prognostic scales designed for metastatic BC have been employed to select fit patients for adequate therapy and enrollment in clinical trials. Different systemic drugs, such as targeted therapies with either monoclonal antibodies or small tyrosine kinase molecules, or modified chemotherapeutic agents are under investigation. Major aims are to improve the penetration of active drugs through the blood-brain barrier (BBB) or brain-tumor barrier (BTB), and establish the best sequence and timing of radiotherapy and systemic therapy to avoid neurocognitive impairment. Moreover, pharmacologic prevention is a new concept driven by the efficacy of targeted agents on macrometastases from specific molecular subgroups. This review aims to provide an overview of the clinical and molecular factors involved in the selection of patients for local and/or systemic therapy, as well as the results of clinical trials on advanced BC. Moreover, insight on promising therapeutic options and potential directions of future therapeutic targets against BBB and microenvironment are discussed.

SUBMITTER: Pellerino A 

PROVIDER: S-EPMC7698162 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Management of Brain and Leptomeningeal Metastases from Breast Cancer.

Pellerino Alessia A   Internò Valeria V   Mo Francesca F   Franchino Federica F   Soffietti Riccardo R   Rudà Roberta R  

International journal of molecular sciences 20201112 22


The management of breast cancer (BC) has rapidly evolved in the last 20 years. The improvement of systemic therapy allows a remarkable control of extracranial disease. However, brain (BM) and leptomeningeal metastases (LM) are frequent complications of advanced BC and represent a challenging issue for clinicians. Some prognostic scales designed for metastatic BC have been employed to select fit patients for adequate therapy and enrollment in clinical trials. Different systemic drugs, such as tar  ...[more]

Similar Datasets

| S-EPMC8633750 | biostudies-literature
| S-EPMC8407522 | biostudies-literature
| S-EPMC6094962 | biostudies-literature
| S-EPMC5512361 | biostudies-other
| S-EPMC5627687 | biostudies-literature
| S-EPMC10567705 | biostudies-literature
| S-EPMC3383009 | biostudies-literature
| S-EPMC4570757 | biostudies-literature
| S-EPMC4657380 | biostudies-literature
| S-EPMC7782834 | biostudies-literature